The University of Texas M.D. Anderson Cancer Center is a freestanding, categorical academic institution established within the University of Texas System by the Texas legislature in Houston in 1941. In 1954, the M.D. Anderson was moved to its current location in the Texas Medical Center in close proximity to other leading biomedical research institutions. The mission of the M.D. Anderson is to eliminate cancer and allied diseases as significant health problems throughout Texas, the nation and the world by developing and maintaining integrated quality programs in patient care, research, education and prevention. M.D. Anderson is dedicated wholly to the study of cancer involving a continuum of research in the basic sciences, clinical investigations and population- based research, with an emphasis on multi-disciplinary translational activities. Faculty investigators are engaged in the transfer of new technology and basic laboratory advances to the clinic, in providing cutting-edge clinical programs including both inpatient and outpatient care, and in community outreach aimed primarily at screening and early detection. The research activities of M.D. Anderson are organized into 28 research programs which include 7 basic science research programs, 18 clinical research programs consisting of 11 disciplinary disease-site programs and 7 thematic programs, and 3 population-based research programs as described in this renewal. The research is supported by the 13 CCSG Core Facilities described in the application for which funding is requested These include 11 currently funded facilities: Automated Cytometry and Cell sorter/Confocal Microscopy and Image Analysis, High Resolution Electron Microscope. Tissue Procurement and Banking, Centralized Histopathology, Research Animal Support, Veterinary Research Support, Cancer Information Systems, Biostatistical Resource Group, Macromolecular Analysis, Synthetic Antigen Laboratory, and Clinical Trials Support, as well as two new facilities, the Pharmacology and Analytical Center and a Central Media Laboratory. Funds are also requested for the Protocol Review and Monitoring System, for Center and a Central Media Laboratory. Funds are also requested for the Protocol Review and Monitoring System, for Development, Planning and Evaluation, and for partial salary support for Senior Leadership and Program Directors.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016672-23
Application #
2688007
Study Section
Subcommittee G - Education (NCI)
Program Officer
Bhorjee, Jaswant
Project Start
1978-07-01
Project End
2003-06-30
Budget Start
1998-09-04
Budget End
1999-06-30
Support Year
23
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
Other Domestic Higher Education
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Scruggs, Stacie; Mama, Scherezade K; Carmack, Cindy L et al. (2018) Randomized Trial of a Lifestyle Physical Activity Intervention for Breast Cancer Survivors: Effects on Transtheoretical Model Variables. Health Promot Pract 19:134-144
Wen, Juyi; Liu, Hongliang; Wang, Lili et al. (2018) Potentially Functional Variants of ATG16L2 Predict Radiation Pneumonitis and Outcomes in Patients with Non-Small Cell Lung Cancer after Definitive Radiotherapy. J Thorac Oncol 13:660-675
Rivera-Del Valle, Nilsa; Cheng, Tiewei; Irwin, Mary E et al. (2018) Combinatorial effects of histone deacetylase inhibitors (HDACi), vorinostat and entinostat, and adaphostin are characterized by distinct redox alterations. Cancer Chemother Pharmacol 81:483-495
Ohanian, Maro; Rozovski, Uri; Kanagal-Shamanna, Rashmi et al. (2018) MYC protein expression is an important prognostic factor in acute myeloid leukemia. Leuk Lymphoma :1-12
Roman-Gonzalez, Alejandro; Zhou, Shouhao; Ayala-Ramirez, Montserrat et al. (2018) Impact of Surgical Resection of the Primary Tumor on Overall Survival in Patients With Metastatic Pheochromocytoma or Sympathetic Paraganglioma. Ann Surg 268:172-178
Wang, Yugang; Guo, Yusong R; Xing, Dongming et al. (2018) Supramolecular assembly of KAT2A with succinyl-CoA for histone succinylation. Cell Discov 4:47
Okuno, Masayuki; Gourmard, Claire; Mizuno, Takashi et al. (2018) Pathological diaphragmatic invasion by colorectal liver metastases is associated with RAS mutation, peritoneal recurrence and worse survival. HPB (Oxford) 20:57-63
Naqvi, Kiran; Cortes, Jorge E; Luthra, Raja et al. (2018) Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR-ABL kinase domain mutations. Int J Hematol 107:689-695
Bose, Prithviraj; Nazha, Aziz; Komrokji, Rami S et al. (2018) Mutational landscape of myelodysplastic/myeloproliferative neoplasm-unclassifiable. Blood 132:2100-2103
Loehrer, Andrew P; Chang, David C; Song, Zirui et al. (2018) Health Reform and Utilization of High-Volume Hospitals for Complex Cancer Operations. J Oncol Pract 14:e42-e50

Showing the most recent 10 out of 12418 publications